Boehringer Ingelheim

By embracing diversity in #ClinicalTrials, we enable more equitable and inclusive healthcare. How can this be achieved? Swipe right to learn more.

We're not only driving innovation ourselves, we're also sharing open source technologies and device development knowledge with others. In order to improve retinal health monitoring we're sharing our software and to best involve patients in device development we provide our blueprint. Want to know more about our approach? Explore here: https://bit.ly/3XicGXt #PatientCentricity #HealthcareInnovation #KnowledgeSharing

#NEWS: The German Vice Chancellor and Federal Minister of Economics Robert Habeck visited our new biomass power plant in Ingelheim today. By using renewable sources, the plant supplies up to 95% of our site's energy needs. This will save around 50,000 tons of CO₂ per year in the future. Learn more about the inauguration and our #sustainability goals: https://bit.ly/3S1dtIS #GreenEnergy

Disparities in clinical trials must become a thing of the past. Inclusion of race, sex, age, genetics, demographics and geographies in clinical trial designs allows us to achieve relevant healthcare solutions that meet the needs of diverse patient populations. Read more here: https://lnkd.in/erYSU5db #ClinicalTrials #Diversity

#NEWS: Our first-in-class SIRPα immuno-oncology program, initiated by OSE Immunotherapeutics, is moving to the next phase in clinical development. Based on the positive data from our first clinical studies and the switch to an improved antibody we aim to provide innovative immuno-oncology treatments to the benefit of more people. Learn more: https://bit.ly/4cHPzd8 #Cancer #ImmunoOncology #ResearchAndDevelopment

“Vision is more than just a function, it’s the sense that people most value, it connects individuals to their way of life.” Read more from our Director of Cardio-Metabolic Diseases Research/Retinal Health, Remko Bakker, as he reflects on our research and development program in #RetinalHealth 👉 https://lnkd.in/eb5YN9Pj

It's essential to raise awareness of the impact that diseases like generalized pustular psoriasis (#GPP) have on people's lives. By collaborating with patient organizations like IFPA, we aim to support their efforts to empower people living with GPP.

#HCP: Tango is a dance in which 2 people communicate through their movements. In the same way, it also takes 2 tests to get the full picture about #ChronicKidneyDisease (CKD). Follow clinical guidelines from diabetes and kidney organizations and issue 2 tests – an eGFR (blood) and UACR (urine) test. Learn more here: https://lnkd.in/eHhyKVMc

Together with the Advisory Board on Cat Diseases (ABCD) we proudly recognize Dr. Katharina Zwicklbauer (Ludwig-Maximilians-Universität München) with the 2024 Young Scientist Award.   Katharina's research on feline infectious peritonitis (FIP), a fatal disease caused by a feline coronavirus, that mostly affects young cats, made important contributions to the field of feline medicine. Just three years ago, there were no treatment options available. Now, there is a whole new product class that we still need to fully explore. In her controlled study, Katharina evaluated different oral formulations of these new antivirals and showed promising results on the clinical evolution and virological parameters. #LifeForward

#NEWS: We're launching the Phase 1 study of BI 3034701, a potential first-in-class, triple agonist obesity treatment developed in our partnership with Gubra. Discover how we are advancing our comprehensive strategy at https://bit.ly/4blrbNu #CardioMetabolic #ResearchCollaboration #Innovation